首頁 > 市場調查報告書 > 製藥

生物製劑

免疫療法藥物市場規模、佔有率和成長分析（按類型、應用、給藥途徑、分銷管道、最終用戶和地區分類）－2026-2033年產業預測

市場調查報告書

商品編碼

1897536

免疫療法藥物市場規模、佔有率和成長分析（按類型、應用、給藥途徑、分銷管道、最終用戶和地區分類）－2026-2033年產業預測

Immunotherapy Drugs Market Size, Share, and Growth Analysis, By Type (Antibody Drugs Inhibitor Drugs, Interferons & Interleukins), By Application, By Route of Administration, By Distribution Channel, By End User, By Region - Industry Forecast 2026-2033

出版日期: 2025年12月19日 | 出版商:

SkyQuest | 英文 174 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

預計到 2024 年，免疫療法藥物市場規模將達到 3,289.5 億美元，到 2025 年將達到 3,792.8 億美元，到 2033 年將達到 11,846.6 億美元，預測期（2026-2033 年）的複合年成長率為 15.3%。

受慢性疾病（包括糖尿病）日益增多的推動，免疫療法市場正經歷顯著成長。這些疾病影響著全球數百萬人口。該領域的企業正日益重視創新產品開發和策略合作，以加強其研發投入。疫情期間，人們對免疫療法的關注度顯著提升，導致其需求激增，凸顯了單株抗體等治療方法在治療重症病例方面的有效性。監管機構正積極核准更多免疫療法產品，進一步推動市場擴張。促成這一成長的關鍵因素包括：從傳統療法轉向標靶治療的轉變、生物相似藥的出現、與文明病相關的健康問題以及對單株抗體需求的激增。此外，生技和製藥公司在研發舉措的合作與投入不斷增加，也推動了市場的發展。

免疫療法市場促進因素

免疫療法藥物市場受到慢性疾病（包括癌症、自體免疫疾病和感染疾病）發病率上升的顯著影響。隨著人口老化和生活方式的改變，對有效治療方法的需求持續成長。免疫療法具有潛在的治癒潛力，進一步推動了其廣泛應用和市場成長。此外，公眾意識的提高和診斷能力的提升也促進了對這些創新治療方法的需求激增。這些因素共同塑造了免疫療法藥物市場，並凸顯了開發先進治療方案以應對各種健康挑戰的必要性。

免疫療法市場限制因素

由於藥物研發的複雜性和高成本，免疫療法市場面臨許多限制因素。臨床試驗、研究和開發所需的大量資金投入，為新型治療方法進入市場設置了障礙。此外，免疫系統各組成部分之間的複雜相互作用，要求治療方法必須針對每位患者或特定病患小組進行個別化客製化。這些挑戰共同阻礙了創新療法的進步，並阻止了潛在的新進入者進入市場。因此，這些限制因素正在減緩整體市場成長和新型免疫療法方案的進展。

免疫療法藥物市場趨勢

在基因組學、精準醫療和基因工程的推動下，免疫療法市場正經歷著向個人化醫療的重大轉變。這一新興趨勢著重於根據患者獨特的基因組成、疾病史和免疫特徵來客製化免疫療法，從而提高療效並最大限度地減少副作用。隨著臨床試驗展現出個人化免疫療法的良好前景，預計企業將加大投資，推動研發活動。這項變革有望徹底改變包括癌症和自體免疫在內的多種疾病的治療方法，並推動免疫療法領域的持續成長。

北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 義大利
- 其他歐洲地區
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 亞太其他地區
拉丁美洲
- 巴西
- 其他拉丁美洲地區
中東和非洲（MEA）
- 海灣合作理事會國家
- 南非
- 其他中東和非洲地區

競爭格局

前五大公司對比
主要企業的市場定位（2025 年）
主要市場參與者所採取的策略
近期市集活動
主要企業市佔率（2025 年）

主要企業簡介

Merck & Co., Inc.（United States）
Johnson & Johnson Services, Inc.（United States）
F. Hoffmann-La Roche Ltd.（Switzerland）
AstraZeneca（United Kingdom）
Pfizer Inc.（United States）
Amgen Inc.（United States）
Novartis AG（Switzerland）
Eli Lilly and Company（United States）
Sanofi（France）
Bristol-Myers Squibb Company（United States）
Gilead Sciences, Inc.（United States）
Takeda Pharmaceutical Company Limited（Japan）
Teva Pharmaceutical Industries Ltd.（Israel）
AbbVie Inc.（United States）
GSK PLC（United Kingdom）
Immunocore Holdings Plc（United Kingdom）
Astellas Pharma Inc.（Japan）
Genmab A/S（Denmark）
MacroGenics, Inc.（United States）
Ferring BV（Switzerland）

簡介目錄

Product Code: SQMIG35I2354

Immunotherapy Drugs Market size was valued at USD 328.95 Billion in 2024 and is poised to grow from USD 379.28 Billion in 2025 to USD 1184.66 Billion by 2033, growing at a CAGR of 15.3% during the forecast period (2026-2033).

The immunotherapy drugs market is experiencing significant growth driven by the rising prevalence of chronic diseases, notably diabetes, affecting millions worldwide. Companies in this sector are increasingly focusing on innovative product development and strategic partnerships to enhance research efforts. The demand for immunotherapy escalated due to heightened attention during the pandemic, highlighting the efficacy of treatments like monoclonal antibodies in managing severe cases. Regulatory bodies are actively approving more immunotherapy products, further fueling market expansion. Key factors contributing to this growth include the shift towards targeted therapies over conventional treatments, the emergence of biosimilars, lifestyle-related health issues, and a surging demand for monoclonal antibodies. Additionally, heightened collaborations and investments in R&D initiatives by biotechnology and pharmaceutical firms are propelling market advancements.

Top-down and bottom-up approaches were used to estimate and validate the size of the Immunotherapy Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Immunotherapy Drugs Market Segments Analysis

Global Immunotherapy Drugs Market is segmented by Type, Route of Administration, Application, Distribution Channel, End User and Region. Based on Type, the market is segmented into Antibody Drugs Inhibitor Drugs, Interferons and Interleukins, Cancer Vaccines, and Other Types. Based on Route of Administration, the market is segmented into Intravenous, Subcutaneous, and Other Routes of Administration. Based on Application, the market is segmented into Cancer, Autoimmune and Inflammatory Diseases, Hematology, Osteology, Neurology, and Other Applications. Based on Distribution Channel, the market is segmented into Retail Pharmacies, Online Pharmacies, and Hospital Pharmacies. Based on End User, the market is segmented into Hospitals, Long-Term Care Facilities, and Other End Users. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & and Africa.

Driver of the Immunotherapy Drugs Market

The immunotherapy drugs market is significantly influenced by the rising incidence of chronic illnesses, including cancer, autoimmune disorders, and infectious diseases. As populations age and lifestyle changes occur, the demand for effective treatment options continues to grow. Immunotherapies offer the promise of potential cures, which further fuels their adoption and market expansion. Moreover, heightened awareness and improved diagnostic capabilities are contributing to the surging demand for these innovative therapies. This combination of factors is essential in shaping the landscape of the immunotherapy pharmaceuticals market, emphasizing the need for advanced treatment solutions in response to widespread health challenges.

Restraints in the Immunotherapy Drugs Market

The immunotherapy drugs market faces significant constraints due to the challenging nature of drug development, which is both complex and costly. The substantial financial investments needed for clinical trials, research, and development create barriers to market entry for new therapies. Additionally, the intricate interactions among immune system components require therapies to be tailored specifically to individual patients or specific patient groups. These challenges collectively hinder the progression of innovative treatments and deter potential new entrants from participating in the market. Consequently, these limitations contribute to a slowdown in overall market growth and the advancement of novel immunotherapeutic options.

Market Trends of the Immunotherapy Drugs Market

The Immunotherapy Drugs market is experiencing a significant shift towards personalized medicine, propelled by advancements in genomics, precision medicine, and genetic engineering. This burgeoning trend focuses on tailoring immunotherapy treatments to individual patients based on their unique genetic compositions, disease histories, and immune profiles, resulting in enhanced therapeutic efficacy and minimized side effects. As clinical trials demonstrate the promising outcomes of personalized immunotherapies, increased investment from businesses is expected to bolster research and development initiatives. This evolution is poised to revolutionize treatment modalities for various conditions, including cancers and autoimmune disorders, thereby driving sustained growth within the immunotherapy sector.

Introduction

Objectives of the Study
Definitions
Market Scope

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Market Overview Outlook
Supply Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers

Key Market Insights

Key Success Factor
Degree of Competition
Top Investment Pockets
Ecosystem of the Market
Customer & Buying Criteria Analysis
Value Chain Analysis
Supply Chain Analysis
Pricing Analysis
Patent Analysis
Technology Analysis
Case Study Analysis
Regulatory Landscape

Immunotherapy Drugs Market, By Type

Market Overview
Antibody Drugs
Inhibitor Drugs
Interferons & Interleukins
Cancer Vaccines
Other Immunotherapy Drugs

Immunotherapy Drugs Market, By Route of Administration

Market Overview
Intravenous Route of Administration
Subcutaneous Route of Administration
Other Routes of Administration

Immunotherapy Drugs Market, By Application

Market Overview
Cancer
Autoimmune & Inflammatory Diseases
Hematology
Osteology
Neurology
Other Applications

Immunotherapy Drugs Market, By Distribution Channel

Market Overview
Retail Pharmacies
Online Pharmacies
Hospital Pharmacies

Immunotherapy Drugs Market, By End User

Market Overview
Hospitals & Clinics
Ambulatory Surgical Centers
Others

Immunotherapy Drugs Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Activities in the Market
Key Companies Market Share (%), 2025

Key Company Profiles

Merck & Co., Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Johnson & Johnson Services, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
F. Hoffmann-La Roche Ltd. (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AstraZeneca (United Kingdom)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Amgen Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eli Lilly and Company (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sanofi (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bristol-Myers Squibb Company (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Gilead Sciences, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Takeda Pharmaceutical Company Limited (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Teva Pharmaceutical Industries Ltd. (Israel)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AbbVie Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GSK PLC (United Kingdom)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Immunocore Holdings Plc (United Kingdom)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Astellas Pharma Inc. (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Genmab A/S (Denmark)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
MacroGenics, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Ferring BV (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments